Iterum Therapeutics Plc Stock In The News
| ITRM Stock | USD 1.33 0.07 5.00% |
Our overall analysis of Iterum Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Iterum Therapeutics PLC. The specific impact of Iterum Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Iterum Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Iterum Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Iterum Therapeutics Backtesting and Iterum Therapeutics Hype Analysis.
Iterum |
Iterum Therapeutics Today Top News and Investor Outlook
Iterum Therapeutics PLC Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Iterum and other traded companies coverage with news coverage. We help investors stay connected with Iterum headlines for the 3rd of March to make an informed investment decision based on correlating the impacts of news items on Iterum Stock performance. Please note that trading solely based on the Iterum Therapeutics PLC hype is not for everyone as timely availability and quick action are needed to avoid losses.
Iterum Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Iterum earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Iterum Therapeutics that are available to investors today. That information is available publicly through Iterum media outlets and privately through word of mouth or via Iterum internal channels. However, regardless of the origin, that massive amount of Iterum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iterum Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iterum Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iterum Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iterum Therapeutics alpha.
Iterum Largest EPS Surprises
Earnings surprises can significantly impact Iterum Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.21 | -0.24 | -0.03 | 14 | ||
2025-02-07 | 2024-12-31 | -0.24 | -0.12 | 0.12 | 50 | ||
2024-08-09 | 2024-06-30 | -0.45 | -0.3 | 0.15 | 33 | ||
2023-08-11 | 2023-06-30 | -0.79 | -0.95 | -0.16 | 20 | ||
2024-05-13 | 2024-03-31 | -0.72 | -0.46 | 0.26 | 36 | ||
2022-03-28 | 2021-12-31 | -0.6 | -0.3 | 0.3 | 50 |
Iterum Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Iterum Therapeutics PLC Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of February 2025
Acquisition by Corey Fishman of 14333 shares of Iterum Therapeutics subject to Rule 16b-3 at MacroaxisInsider
7th of February 2025
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results at gurufocus.com
31st of January 2025
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Febru... at finance.yahoo.com
9th of December 2024
Disposition of 36798 shares by Dunne Michael W. of Iterum Therapeutics subject to Rule 16b... at MacroaxisInsider
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iterum Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iterum Therapeutics' short interest history, or implied volatility extrapolated from Iterum Therapeutics options trading.
Check out Iterum Therapeutics Backtesting and Iterum Therapeutics Hype Analysis. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.